Related Experiment Video

Updated: Jun 11, 2026

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals
09:31

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals

Published on: April 15, 2017

Oseltamivir dosing for influenza infection in premature neonates

Edward P Acosta1, Penelope Jester, Peter Gal

  • 1Division of Clinical Pharmacology, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294, USA. eacosta@uab.edu

The Journal of Infectious Diseases
|July 3, 2010
PubMed

Insights

Oseltamivir dosing for premature infants with influenza A (H1N1) was evaluated. A 1.0 mg/kg twice-daily dose provides similar drug exposure to older children, offering crucial guidance for this vulnerable group.

Area of Science:

  • Pediatric Pharmacology
  • Infectious Diseases
  • Neonatal Care

Background:

  • Oseltamivir is authorized for treating influenza A (H1N1) in children under one year.
  • No established dosing guidelines exist for oseltamivir in premature infants.
  • Influenza A (H1N1) poses a significant risk to neonates.

Purpose of the Study:

  • To evaluate the pharmacokinetics and determine appropriate oseltamivir dosage in premature infants.
  • To establish safe and effective oseltamivir dosing for neonates with influenza A (H1N1).

Main Methods:

  • A pharmacokinetic study was conducted in 32 neonatal intensive care unit (NICU) infants exposed to influenza A (H1N1).
  • Oseltamivir carboxylate levels were measured to assess drug exposure.
  • Dosage adjustments were made based on pharmacokinetic data.

Main Results:

  • A dosage of 1.0 mg/kg twice daily in premature infants resulted in oseltamivir carboxylate exposures comparable to older children receiving 3.0 mg/kg twice daily.
  • This dosage regimen suggests potential efficacy and safety in neonates.

Conclusions:

  • The study provides initial evidence supporting a 1.0 mg/kg twice-daily oseltamivir dosage for premature infants.
  • This finding offers critical guidance for managing influenza A (H1N1) in this high-risk neonatal population.

More Related Videos

Optimization of a Quantitative Micro-neutralization Assay10:09

Optimization of a Quantitative Micro-neutralization Assay

Published on: December 14, 2016

Modeling Dysplastic and Functional Lung Alveolar Repair after Influenza Infection07:45

Modeling Dysplastic and Functional Lung Alveolar Repair after Influenza Infection

Published on: September 19, 2025

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
IV Infusion to Oral Dosing: Conversion Methods01:28

IV Infusion to Oral Dosing: Conversion Methods

The development of extended-release formulations has facilitated the transition from intravenous to oral medication, offering a more convenient and patient-friendly approach to drug administration. This transition, however, requires careful management to ensure that therapeutic drug levels are maintained, preserving efficacy and avoiding adverse effects. Understanding pharmacokinetic principles and dosage calculations is critical during this process.Pharmacokinetics of the...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...